- Home
- PETZ vs RLMD Comparison
PETZ vs RLMD Comparison
Compare PETZ & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- RLMD
- Stock Information
- Founded
- PETZ 2002
- RLMD 2004
- Country
- PETZ China
- RLMD United States
- Employees
- PETZ N/A
- RLMD N/A
- Industry
- PETZ Steel/Iron Ore
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- RLMD Health Care
- Exchange
- PETZ Nasdaq
- RLMD Nasdaq
- Market Cap
- PETZ 10.3M
- RLMD 11.5M
- IPO Year
- PETZ 2017
- RLMD N/A
- Fundamental
- Price
- PETZ $1.05
- RLMD $0.65
- Analyst Decision
- PETZ
- RLMD Hold
- Analyst Count
- PETZ 0
- RLMD 4
- Target Price
- PETZ N/A
- RLMD $4.25
- AVG Volume (30 Days)
- PETZ 6.9K
- RLMD 3.1M
- Earning Date
- PETZ 05-06-2025
- RLMD 05-07-2025
- Dividend Yield
- PETZ N/A
- RLMD N/A
- EPS Growth
- PETZ N/A
- RLMD N/A
- EPS
- PETZ N/A
- RLMD N/A
- Revenue
- PETZ $3,278,453.00
- RLMD N/A
- Revenue This Year
- PETZ N/A
- RLMD N/A
- Revenue Next Year
- PETZ N/A
- RLMD N/A
- P/E Ratio
- PETZ N/A
- RLMD N/A
- Revenue Growth
- PETZ 2.46
- RLMD N/A
- 52 Week Low
- PETZ $0.99
- RLMD $0.24
- 52 Week High
- PETZ $1.74
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- PETZ 41.66
- RLMD 74.73
- Support Level
- PETZ $0.99
- RLMD $0.27
- Resistance Level
- PETZ $1.06
- RLMD $0.76
- Average True Range (ATR)
- PETZ 0.06
- RLMD 0.08
- MACD
- PETZ 0.01
- RLMD 0.05
- Stochastic Oscillator
- PETZ 37.50
- RLMD 78.54
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.